Cory Renauer
Value, long-term horizon, dividend investing, dividend growth investing

Sarepta And Eteplirsen: Will 12 Patients Be Enough For The FDA?

Sarepta Therapeutics (NASDAQ:SRPT) creates RNA-based drugs for the treatment of serious and life threatening diseases. Its most advanced candidate is an intravenously delivered treatment for Duchenne Muscular Dystrophy [DMD]. In addition to the promising DMD program, the company also has drugs for the treatment ...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
WITH SEEKING ALPHA PRO, INVESTORS CAN ALSO:
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
You are protected by the Seeking Alpha Money Back Guarantee and will get a prompt refund on the unused portion of your subscription at any time, for any reason.